No Detail Found!

Outcomes of Haematopoietic Stem Cell Transplantation in Beta Thalassemia Major with Fully Matched Parents as Donor

Author(s)
Asghar Ali Kerio Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Nighat Shahbaz Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Tariq Azam Khattak Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Tariq Ghafoor Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Muhammad Farhan Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Hashim Khan Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre,Rawalpindi,Pakistan
Abstract
Objective: To determine the outcome of beta thalassemia major (BTM) patients undergoing haematopoietic stem cells (HSCT), with fully matched parents as donors vs. matched sibling donors (MSD). Study Design: Observational Study. Place and Duration of the Study: Department of Clinical Haematology and Bone Marrow Transplantation Centre, Rawalpindi, Pakistan, from January 2013 to July 2023. Methodology: Group A consisted of BTM patients who underwent HSCT with fully matched siblings as donors, and Group B consisted of BTM patients who underwent HSCT with fully matched parents as donors. Study data included the age and gender of both recipients and donors, source and dose of stem cells infused, and stage and grades of acute and chronic graft versus host disease (GvHD). All patients received Myeloablative conditioning regimen (MAC). Data were collected to assess patients demographics, response to HSCT, remission rate, disease free survival (DFS), relapse, and GvHD free survival (GRFS), and overall survival (OS). Results: The mean age of the 54 patients was 5.90 ± 3.29 years. The mean TNC and CD34 doses were 4.99 + 1.13 and 5.42 + 3.70, respectively. Mean time for neutrophil engraftment in both groups was 14.88 + 4.51 days and platelets engraftment was 23.0 + 5.35 days. Most common cause of death was neutropenic sepsis followed by aGVHD. Seven patients had graft rejection. There was no signi cant association found between graft rejection with donor relation though graft rejection was higher in OS in this study was 70.4%. OS was equal in both groups. Disease free survival was superior in MSD (63%) than parent group (57.7%). Conclusion: Allogenic bone marrow transplantation with parents as donors in BTM patients yields outcomes comparable to those with matched sibling donors. This nding is especially relevant in regions like Pakistan, where donor registries and high-resolution HLA typing may be limited.
Publication Details
Page(s) 279-283
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
Beta thalassemia major, Haematopoietic stem cell transplant, Post-transplant outcome
0

Citations

0

Downloads

107

Views